Trial Profile

A Pivotal Phase III Study to Evaluate DBD (Dibromodulcitol) for Patients with Brain Cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 04 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mitolactol (Primary)
Indications Brain cancer
Focus Registrational; Therapeutic Use
Sponsors Eleison Pharmaceuticals

Most Recent Events

28 May 2021 According to an Eleison Pharmaceuticals media release, the company plans to begin this potentially pivotal phase III study in 2022 or 2023.
21 Dec 2020 New trial record
11 Dec 2020 According to an Eleison Pharmaceuticals media release, the company plans to begin this pivotal phase III study of its DBD (Dibromodulcitol) program for patients with brain cancer in late 2021 or 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com